Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Novus Medical Detox Center: New Synthetic Drugs Evade Legal Risks
  • USA - English


News provided by

JoTo PR

Nov 01, 2016, 08:00 ET

Share this article

Share toX

Share this article

Share toX

Bryn Wesch, CFO for Novus Medical Detox Center, reviews synthetic drug implications for  law enforcement and health and safety risks
Bryn Wesch, CFO for Novus Medical Detox Center, reviews synthetic drug implications for law enforcement and health and safety risks

NEW PORT RICHEY, Fla., (PRWEB) November 01, 2016 -- Synthetic drugs continue to make headlines for their health and safety risks and the challenges they pose for health officials and law enforcement.(1) Most recently, two Utah teens died of a suspected overdose on the synthetic opioid U-47700, also known as “Pink,” which was legally purchased online.(2)Novus Medical Detox Center, a leading Florida-based drug treatment facility, aims to increase awareness of the dangers associated with synthetic drugs and advocates for measures that can provide a solution.

Synthetic drugs are poised to become a national crisis unless immediate action is taken, and the solution will require coordination across multiple fronts.

Post this

Synthetic drugs began gaining popularity in the United States in 2010, but have proven very difficult to regulate; when one substance is banned, manufacturers can change a single molecule of that illegal drug and essentially render it “legal”.(1) While some synthetic drugs were originally developed for pharmaceutical use, many new “analog drugs” were designed to mimic the effects of controlled substances while evading existing laws. These drugs include synthetic cannabinoids (Spice, K2), synthetic stimulants/hallucinogens (MDMA, “bath salts”, flakka) and synthetic opioids (fentanyl, W-18, U-47700). Many are available online and marketed as a “legal” way to get high; sellers often label them as “research chemicals” or “not for human consumption” to circumvent current laws.(3)

Though the legal status of synthetic drugs may be questionable, their dangerous consequences are widely documented. In Broward County, Florida, 360 flakka (alpha-PVP) users were hospitalized in a single month and 61 people died over a 16-month period; in the District of Columbia, 603 people were taken to the hospital last September after ingesting synthetic cannabinoids.(1) While U-47700 (“Pink”) is relatively new to the market, it has already been implicated in at least 80 deaths this year.(2)

“The ambiguous legal status of synthetic drugs has misled many to believe they are ‘safe’ alternatives to street drugs,” explained Bryn Wesch, chief financial officer for Novus Medical Detox Center. “But in actuality, they are often many times more potent than heroin. Users who experiment with synthetics face a significant risk of overdose or permanent health issues, such as kidney failure; meanwhile, the death toll continues to rise.”

The U.S. Drug Enforcement Administration (DEA) has temporarily placed many synthetic drugs on its controlled substance schedule pending further evaluation, most recently adding U-47700 in September.(2) The lengthy process required for a full federal ban has led many states to implement their own laws, and some are taking a novel approach to outmaneuver drug manufacturers. Both Florida and the District of Columbia have enacted new laws that classify substances “based on the type of drug and the reaction it causes,” as opposed to its chemical makeup, so “any drug that mimics an already illicit substance will automatically be illegal.”(1)

“Synthetic drugs are poised to become a national crisis unless immediate action is taken, and the solution will require coordination across multiple fronts,” asserted Wesch. “From a legal perspective, the federal government and other states should follow Florida’s lead in banning broader classes of synthetic drugs—it’s the only way to prevent manufacturers from skirting the law with constant reformulation, and it will enable law enforcement to permanently shut down manufacturers and sellers.”

Wesch also cites a need for widespread education efforts to help the public understand just how dangerous, and even deadly, these substances can be; and she advocates for expanded access to drug treatment programs. “Addiction and dependency don’t disappear when a drug goes away; like synthetic drugs, they just take new forms. Detox and rehab can help those with substance use disorders reclaim their lives from drugs, once and for all,” she concluded.

Novus offers medically supervised detox programs designed to relieve the pain and discomfort of withdrawal. The Florida drug detox facility provides individually customized treatment plans based on proven medical protocols, including 24-hour access to nursing care and withdrawal specialists. Novus is renowned for its expertise in treating high-dose methadone cases, and is proficient in detoxing patients from other high-dose substances just as safely, comfortably and effectively.

For more information on Novus Medical Detox Center and its drug treatment programs, visit http://www.novusdetox.com.

About Novus Medical Detox Center:
Novus Medical Detox Center has earned The Joint Commission’s Gold Seal of Approval for Behavioral Health Care Accreditation as an inpatient medical detox facility. Licensed by the Florida Department of Children and Families, Novus provides safe, effective alcohol and drug treatment programs that are based on proven medical protocols and designed to minimize the discomfort of withdrawal. The facility is located on 3.25 acres in New Port Richey, Florida, in a tranquil, spa-like setting bordering protected conservation land. Intent on proving that detox doesn’t have to be painful or degrading, Novus set out to transform the industry by bringing humanity into medical detox with individually customized treatment programs and 24/7 access to nursing care and withdrawal specialists. Today, Novus is renowned as a champion of industry standardization and a staunch advocate of patients fighting to overcome substance use disorders. Frequently recognized for its contributions to the industry and local community, Novus has become a regular source to media publications such as The Wall Street Journal and USA Today, and has ranked in the Tampa Bay Business Journal’s Fast 50, the Florida Business Journal’s Top 500 and the Inc. 5000 list of America’s fastest-growing companies. For more information on Novus’ medically supervised detox programs, visit http://novusdetox.com.

1. Breitenbach, Sarah. “Synthetic Drugs Send States Scrambling”; The Pew Charitable Trusts; April 29, 2016. pewtrusts.org/en/research-and-analysis/blogs/stateline/2016/04/29/synthetic-drugs-send-states-scrambling

2. Blankstein, Andrew. “Pink: Stronger Than Heroin, But Legal in Most States”; NBC News; October 15, 2016. nbcnews.com/storyline/americas-heroin-epidemic/pink-stronger-heroin-legal-most-states-n666446

3. Roth, Amy Neff. “New Drugs a Click Away”; Utica Observer-Dispatch; July 17, 2016. uticaod.com/news/20160717/new-drugs-click-away

Karla Jo Helms, JoTo PR, +1 (888) 202-4614 Ext: 802, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.